Johnson & Johnson Returns to CIIE with Premier Innovations Under the Theme 'Innovation for a Healthier Future'

SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- The 4th China International Import Expo (CIIE) is about to kick off. This year, global healthcare leader Johnson & Johnson will attend the event for the fourth consecutive year, bringing a host of innovative products and technologies from its Medical Devices, Pharmaceutical, Consumer, and Vision business sectors that will make their China or even global debuts. As one of the largest exhibitors in the Medical Equipment and Healthcare Products exhibition area, Johnson & Johnson will continue to serve as a council member of the Exhibitors Alliance Council at this CIIE, and will also assume the role of vice president of the newly established Medical Devices Professional Committee under the Alliance. The company is committed to driving innovation on the CIIE platform and contributing to the advancement of China's healthcare industry.

Located in the core area of the main aisle within the Medical Devices & Healthcare Zone (Hall 7.2H), the Johnson & Johnson booth, themed "Innovation Drives a Healthier Future," features a design that carries forward Johnson & Johnson's classic red-and-white color scheme. Spanning approximately 1,000 square meters, it comprehensively showcases innovative highlights across its business portfolios, while a series of strategic cooperation and procurement agreements will be signed with government authorities and partners from various sectors. At the same time, it will also...will hold a newAt the press conference, Johnson & Johnson highlighted its advancements in digital development, key product promotion, and innovative collaboration, demonstrating its industry commitment to advancing a healthier future through innovation.

"The CIIE's 'circle of friends' continues to expand, highlighting the tremendous magnetic appeal of this open international trade platform to enterprises. As a 'four-session veteran' of the CIIE, we have truly experienced the 'multiplier' exposure effect and the 'accelerating' boost effect of this vital platform," said Song Weiqun, Senior Vice President of Johnson & Johnson Global and Chairman of Greater China. "Johnson & Johnson looks forward to participating in this year's CIIE with great anticipation. We will showcase more globally leading innovative products, safeguarding the health of the Chinese people while actively promoting industrial innovation and open cooperation."

In the medical device sector, Johnson & Johnson remains steadfast in its commitment to patient care. Addressing the health needs of the Chinese public and critical healthcare challenges, the company is accelerating the introduction of globally leading medical solutions into China, actively promoting the development and widespread adoption of minimally invasive and even non-invasive surgical procedures, and driving the future development of China's healthcare sector. At this year's China International Import Expo (CIIE), Johnson & Johnson MedTech will showcase multiple innovative products making their debut across its three business segments: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Among them are a globally leading digital platform for early cancer diagnosis and treatment, and Monarch, the world's first incisionless transbronchial digital surgical platform for lung cancer diagnosis and treatment.^TMbyand the world's firstThe NuVera 4D intracardiac echocardiography diagnostic catheter system, enabling real-time visualization of three-dimensional intracardiac anatomy, will make its "Asian debut"; allWorld's Only BeltAntimicrobial-coated cutting knotless absorbable suture STRATAFIX Spiral Plus, DYNACORD-equipped suture designed to promote improved postoperative healing of soft tissue and bone^TMSelf-expanding PEEK suture anchors and a digital orthognathic system capable of providing precise virtual surgical planning tailored to personalized needs will make their "China debut."

Monarch(TM) Digital Surgical Platform

Notably, this year marks the 20th anniversary of Johnson & Johnson MedTech Professional Education's entry into China. Leveraging its core expertise, Johnson & Johnson MedTech has been delivering professional education across China, establishing dedicated academies and education centers in Shanghai, Beijing, and Boao. Backed by globally leading educational capabilities, the company supports the continuous, career-long professional development of generations of Chinese healthcare professionals. By actively promoting the adoption of innovative surgical techniques, Johnson & Johnson MedTech is contributing to the advancement of China's healthcare industry.

In the pharmaceutical sector, Janssen, the pharmaceutical subsidiary of Johnson & Johnson, has upheld its original commitment that “patients are waiting” throughout its 36 years in China. Grounded in science, the company has continuously introduced breakthrough product portfolios and proprietary solutions, while steadily optimizing patient access to medicines and innovative service models to meet China’s growing healthcare needs. Since 2017, 28 innovative drugs and new indications from Janssen have been approved or launched in China. At this CIIE, Janssen showcased innovative drugs across multiple therapeutic areas, including solid tumors, hematological malignancies, rare diseases, and neuroscience, featuring the targeted anti-lung cancer drug making its “Asian debut” -- Amivantamab, which isWorld's First ApprovedA targeted therapeutic agent indicated for adult patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, alongside the "China debut" drug Zhaokesu^®is an innovative drug that has just been approved by China's National Medical Products Administration (NMPA) for the treatment of newly diagnosed primary light-chain amyloidosis.

Janssen's "Asian Debut" Targeted Anti-Lung Cancer Drug Amivantamab

Johnson & Johnson's Eye Health business -- Johnson & Johnson Vision will showcase multiple new ACUVUE-branded contact lenses, a range of advanced cataract surgery devices and intraocular lenses, as well as dry eye diagnostic and treatment devices at this year's CIIE. Among them, as the world's first drug-eluting contact lens approved by regulatory authorities for commercial launch, ACUVUE^®Theravision will make its debut in China, representing a significant breakthrough in innovative ophthalmic sustained-release drug delivery technology. In the field of cataract treatment, Johnson & Johnson Vision will showcase its next-generation extended depth of focus (EDOF) intraocular lens, TECNIS Synergy, which features enhanced diffractive grating technology integrated with multifocal optics.^®, it embodies the advanced technology of Johnson & Johnson’s extended depth of focus intraocular lens platform, which has been commercially launched and is in use across multiple countries in Europe and the United States, helping people achieve clearer vision and a better quality of life.

The World's First Regulatory-Approved Drug-Eluting Contact Lens Product: ACUVUE® Theravision

In the consumer sector, multiple globally renowned brands under Johnson & Johnson will unveil flagship new products making their global debut, specifically customized for the Chinese market. Spanning categories such as personal health care, maternal and infant care, and professional skincare, these launches will comprehensively showcase Johnson & Johnson's scientific core and health commitment within the consumer domain. Johnson & Johnson will introduce a total of 41 debut products, including Children's Cetirizine Hydrochloride Anti-Allergy Syrup, and will present Nicorette^®A sugar-free, fruit-flavored nicotine lozenge for smoking cessation. Listerine will launch the world’s first oral care product specifically formulated for smokers; Aveeno, a renowned North American natural skincare brand specializing in maternal and infant care, will introduce four new baby skincare products; Dr. Ci:Labo will unveil a new anti-aging and firming serum, alongside a complete lineup of new products across its whitening and fruit acid (AHA) exfoliation series; Neutrogena, a pioneer in early anti-aging skincare, will also introduce a new retinol series tailored for sensitive skin this year, following last year’s launch of a retinol line specifically customized for Chinese consumers. In recent years, Johnson & Johnson has established multiple new consumer and personal care segments in China, focusing on health-centric, science-driven innovations. By leveraging China’s unique and globally leading digital ecosystem, the company will develop a series of products that embody localized digital innovation, thereby facilitating the expansion of China-originated digital solutions into the global market.

Aveeno Baby Moana Premium Series Soothing & Softening Lightweight Moisturizing Lotion

The "spillover effect" of Johnson & Johnson's exhibition participation continues to manifest, yielding fruitful results from the implementation of innovative products and solutions to open collaborative innovation. For example, Johnson & Johnson Vision’s "Catalys" ophthalmic femtosecond laser treatment system was introduced to China at the end of 2019 through the "pilot trial" policy in Boao, Hainan. It made a grand debut during the 3rd China International Import Expo (CIIE) in 2020, quickly familiarizing industry professionals with its series of advantages, including high accuracy, high precision, and high safety, thereby laying a solid foundation for its subsequent nationwide promotion. Currently, the "Catalys" system has been deployed in multiple cities across China, serving the needs of patients and surgeons alike. At this CIIE, the Catalys mobile surgical bed, designed to be used in conjunction with the system, will also be showcased. This mobile operating table connects to the main console via wireless Bluetooth, enabling a seamless "patient-remains-on-bed" workflow from preoperative preparation and intraoperative transfer to postoperative departure. Featuring an ergonomically designed headrest and a flexibly adjustable segmented bed surface, it allows patients to maintain a more comfortable position throughout the preoperative, intraoperative, and postoperative phases.

“China has become one of the fastest-growing markets for Johnson & Johnson’s global business and a key market for its global ‘Growth + Innovation’ dual-engine strategy. With the continuous deepening of the ‘dual circulation’ new development paradigm and the comprehensive advancement of the ‘Healthy China’ strategy, Johnson & Johnson will increase its investment in China and its commitment to innovation to serve the health needs of the public, and will continue to collaborate with the government, industry partners, and other stakeholders to deliver more innovative solutions, making continuous and positive contributions to improving human health and well-being and advancing toward a healthier future for humanity!” said Song Weiqun, Senior Vice President of Johnson & Johnson Global and Chairman of the China Region.